

**Table 5.** Continued.

Probe sets	cortex/ papilla	medulla/ papilla	cortex/ medulla	GENE_SYMBOL	GENE_NAME	channel transporter	Metabolic enzymes	cytoskeleton /extracellular matrix
1373667_at	31.8	14.0	2.3	Ccbl1_predicted	cysteine conjugate-beta lyase (predicted)			
1372031_at	31.7	7.5	4.2	Dab2	Disabled homolog 2 (Drosophila)			
1390585_at	31.7	10.9	2.9	Masp1	mannan-binding lectin serine peptidase 1			
1386981_at	31.6	3.7	8.4	Slc16a1	solute carrier family 16 (monocarboxylic acid transporters), member 1			
1368253_at	31.5	28.7	1.1	Gamt	guanidinoacetate methyltransferase			
1388537_at	31.4	15.2	2.1	Nipsnap1_predicted	4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 ( <i>C. elegans</i> ) (predicted)			
1387165_at	31.1	4.4	7.1	Maf	v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog (c-maf)			
1384273_at	30.9	10.2	3.0	Car1_predicted	carbohydrate kinase-like (predicted)			
1380393_at	30.9	30.7	1.0	Cryz_predicted	crystallin, zeta (predicted)			
1393947_at	30.7	12.7	2.4	Slc25a15_predicted	solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 (predicted)			
1378197_at	30.4	9.5	3.2	KIFC2	kinesin family member C2			
1379582_at	30.1	14.5	2.1	Cena2	cyclin A2			
1382434_at	30.0	23.5	1.3	Entpd5	ectonucleoside triphosphate diphosphohydrolase 5			

After selection by ANOVA ( $p < 0.01$ ) for the data of percellome normalization, genes maximally expressed in cortex were selected. The genes were aligned in the order of the ratio to the lower expression value, either in papilla or in medulla. Among the genes listed here, relatively specific ones for cortex (ratio > 3) are shaded in the cortex/medulla column. The genes categorized to "channel/transporters", "metabolic enzymes", or "cytoskeleton/extracellular matrix" are also shaded. Proteases or enzymes involving signal transduction are not included in the category of "metabolic enzymes". For simplicity, genes with less than 30-fold specificity are omitted.

**Table 6.** Regionally specific genes in rat kidney.

	Channel/transporter	Metabolizing enzymes	Cytoskeleton/ extracellular matrix	Others of interest
Papilla	Slco4a1, Aqp3, Aqp4, Fxyd4, Slc4a11, Clcnk1, bsnd	Ptgs1, Ptgs2, Aldh1a3, Akr1b4, Ugt8, Ltb4dh	Capg, Plekhh1, Coll8a1, Spnb3, Hs3st1, Krt1-18	Hspa2, Hspa1a, Hspb1
Medulla	Slc21a1, Slc21a13, Slc23a3, Slc21a9, UST5r, Slc16a18, Slc38a3, Slc22a2, Slc7a12, Slc15a2	CYP2d9, CYP2c, Hnmt, Pklr, Fmo3, Dhrr7, Akr1c12, Gclc, Ggt1, Tmlhe		Prlr, Ace2
Cortex	Ust1r, Slc17a3, Slc26a1, Slc22a12, Slc12a3, Slc16a6, Aqp11, Aqp7, Gjb2, Slc27a2	Sult1b1, Klk7, Ddc, CYP2d26, CYP2e1, CYP4f2, Upb1, Aspa, Acmsd, Dmgdh, Kmo		Ren1

Genes categorized in channel/transporter, metabolizing enzyme and cytoskeleton/extracellular matrix from high rank in Tables 3, 4, 5 are summarized by using gene symbols which can be referred to in the preceding tables. Interesting genes discussed in the text are included as "others".

## Gene expression in rat kidney.

aminoglycoside causes necrosis mainly in the proximal tubules, while puromycin does the same on glomerulus (Schnellmann, 2001). In an organ with such a complex structure, analysis by GeneChip would give different results when it is done as a whole or separated into portions. When the potential nephrotoxicity of candidate chemicals is assessed using toxicogenomics technology, it would be ideal to perform GeneChip analysis for each portion. However, it is sometimes difficult in the usual toxicity tests to obtain enough sample material for toxicogenomics analysis after sampling for other histopathological and biochemical analyses. Furthermore, it is difficult to determine which portion is to be examined when the target region of the test drug is unknown. Analyzing all of the separated portions is impractical considering the cost.

In the present study, comparison of the gene expression profile was made among each portion, papilla, medulla, and cortex, as well as between the whole slice and each portion. Although various genes or proteins with region-specific expression have been reported, their localization was toward glomerulus, distal/proximal tubules, or collecting duct, i.e., tissues from specific cell types, not the anatomical location. This way is of course desirable for cell physiological study, but is inconvenient when a potential bias in the gene expression analysis based on the position of sampling is concerned, and reports focusing on this point are scarce. It can be generally said that papilla is enriched in collecting duct and relatively scarce in glomerulus, but their proportion varies with the sampling.

When comparison between each portion was made by correlation coefficient, the correlation was decreased between the portions compared to within the same portion. The correlation of gene expression profile between cortex and medulla was relatively high, whereas that between papilla and cortex or medulla was low. Based on the correlation of each portion to the whole slice, it was concluded that gene expression in the whole slice largely reflected that of cortex, followed by medulla. The main reason is that the volume of the portion comprising the whole slice is in this order: cortex > medulla > papilla (Fig. 1). If the production of mRNA per cell is constant throughout the portions, the region-specific gene can be extracted by global normalization. However, this was found to be inappropriate.

To extract region-specific genes, detection call (absent, present, and marginal) included in the GeneChip data was utilized, i.e., genes with present

call in a particular region but absent call in all others were extracted, and they were checked as to whether they had present call in the whole slice. The important point of this result is that the majority (94%) of genes specifically expressed in papilla are not detectable in the whole slice. This is consistent with the result of the correlation coefficient. It is thus concluded that the expression changes of such genes occurring in papilla cannot be detected when they are decreased, and it is difficult to measure when they are increased, but their extent is not so large, as in the analysis of the whole slice. Attention should be paid when these genes are used for the marker genes in the toxicogenomics of kidney.

As obvious from Figs. 3 and 4, global normalization of the data leads to an incorrect result in the comparison among different regions. This might be due to the fact that the transcriptional activity in papilla is much less than that in the others, and subsequently the expression of each gene in papilla was over-estimated by the normalization, using a low value. This does not mean that the global normalization is useless when drug effects are tested on the samples separated into different portions. As global normalization gives relative values to the total mRNA amount, it efficiently reveals the drug effect unless the drug brings about a large change in the total mRNA. In the present case, it became problematic simply because the comparison was made among tissues with largely different mRNA contents. An alternative way is to normalize each gene by a house-keeping gene, e.g.,  $\beta$ -actin or GAPDH. However, as already shown above, there is no guarantee that expression of these genes is constant throughout the different tissues.

Based on the data normalized by the percellome procedure, genes with region-specific expression were extracted and aligned in the order of their relative specificity. It was then found that the majority of genes with high region-specificity were related to channel/transporter and metabolic enzyme, suggesting a good correlation between gene expression and physiological function.

There are many known members of the solute carrier family (slc), whose distribution showed an interesting and marked difference among the three portions. In papilla, slc4a family members (anion transporter) were specifically expressed. In medulla, the expression of slc21a family (organic anion transporting polypeptides; OATPs), was outstanding. There were also other members such as Slc23a3 (xanthine/uracil permease), Slc6a18 (monocarboxylic acid trans-

porter), Slc138a3 (SNAT family; Gu *et al.*, 2005), Slc22a2 (organic cation transporter), Slc7a12 (cationic amino acid transporter), and Slc15a2 (H<sup>+</sup>/peptide transporter), which were specifically expressed. In cortex, Slc17a (Na-phosphate co-transporter), Slc22a12 and Slc12a3 (both anion transporters), Slc16a6 (monocarboxylic acid transporter), and Slc27a2 (fatty acid transporter) were found to be specific.

There have been some reports regarding region-specific transporters. As glucose transport is known to be operational in the proximal tubule, it is expected that glucose transporters are enriched in cortex and medulla compared with papilla. Among the genes judged as significant by ANOVA, slc2a4 and 2a13 were glucose transporters and their expression was about 3.5-fold higher in medulla and cortex compared with papilla (this number was not large enough to be shown in the tables). It is also known that slc14a2, involved in urea transport, is highly expressed in the collecting duct (Karakashian *et al.*, 1999). Although the ratio was not large enough to be in Table 3, its expression in papilla was twofold compared with cortex, consistent with the literature.

Aquaporin (Aqp) 3 and 4 were specifically expressed in papilla while Aqp 7 and 11 were in cortex (Table 6). Although the ratio was not large enough to be in Table 3, Aqp 2 was also preferentially expressed in papilla (1.9 and 2.3 fold compared with medulla and cortex, respectively). There have been supportive reports that Aqp2 (Jo *et al.*, 1997) and Aqp3 (Echevarria *et al.*, 1994) are enriched in collecting duct and Aqp7 is highly expressed in cortex (Nejsun *et al.*, 2000).

Kidney produces renin to control blood pressure. Renin is synthesized in juxtaglomerular cells and converts angiotensinogen to angiotensin I, which is further converted to angiotensin II by angiotensin converting enzyme (ACE). The renin gene (Ren1) was expressed highest in cortex while ACE (ace2) was highest in medulla (Table 6).

Probes for prolactin receptor are 4 sets on the chip and all of them showed quite low expression in papilla (expression ranged 60 - 90 fold in cortex and 70 - 130 fold in medulla, compared with papilla, for these 4 probe sets). Prolactin is known as a natriuretic hormone which interacts with the renal dopamine system, and its natriuretic response is associated with inhibition of proximal tubular Na,K-ATPase (Ibarra *et al.*, 2005). The location of its receptor in kidney (enriched in medulla and cortex) elucidated in the present study was consistent with the region where the hormone

works.

NSAID-induced nephrotoxicity is well known as a typical toxicity toward kidney (Schnellmann, 2001). Its mechanism is believed to be inhibition of cyclooxygenase (COX). COX-1 is a constitutive, house-keeping enzyme and reported to be much present in the collecting duct. COX-2 is an inducible enzyme involved in the inflammatory process, while it is reported to be always present at a low level in kidney without inflammation (Harris *et al.*, 1994). The genes for these enzymes (ptgs1 and ptgs2) were both highest in papilla. Moreover, phospholipase A2 IVA was also highest in papilla. These observations are consistent with previous reports and might be related to the fact that nephrotoxicity by NSAID is frequently associated with necrosis in papilla (Schnellmann, 2001).

On the other hand, other prostaglandin-related genes were uniformly low in papilla. The expression of the gene of 15-hydroxyprostaglandin dehydrogenase (Hpgd), which is involved in prostaglandin metabolism, was 60 and 102 fold in medulla and cortex, respectively, compared with papilla. Other prostaglandin-related genes without large enough specificity for the table were prostaglandin D2 synthase (Ptgds), prostaglandin E receptor 1 (Ptger1), prostaglandin E receptor 3 (Ptger3), and prostaglandin E receptor 4 (Ptger4), which were 6- and 26-fold, 3- and 4-fold, 5- and 2-fold, 3- and 6-fold, in medulla and cortex, respectively, compared with papilla. The expression of prostaglandin E synthase (Ptges) was exceptionally the same in papilla and medulla, and 4.5-fold of these was found in cortex.

Kallikrein that produces bradykinin is biosynthesized in kidney cortex (Xiong *et al.*, 1989). Kallikrein 7 (Klk7) is found in Table 5 showing 15-fold and 285-fold expression in medulla and cortex, respectively, compared with papilla. This is again consistent with the anatomical feature.

One unique point in the tables is that genes related to cytoskeletal proteins and heat shock proteins (both HSP70 and HSP27) selectively expressed high in papilla (Table 3 and 6). If the analysis was done by global normalization, it could be that the relative expression of these genes was apparently overestimated because of the low expression of other gene populations, such as transporters or enzymes. However, the present analysis was based on percellome normalization, and the values are directly related to the copy numbers per cell (or DNA). Therefore, enrichment of these genes means that the copy numbers of these genes are actually high. The potential involvement of

## Gene expression in rat kidney.

HSP70 in nephrotoxicity has been investigated in relation to renal cell survival and apoptosis, and the relationship between hsp27 and cytoskeletal proteins has also been discussed in relation to renal injury after ischemia-reperfusion (van de Water, 2006). Its pathophysiological meaning is presently unclear, especially because data of modulation by nephrotoxicants is not available, so this point is quite interesting as a future study.

In summary, many of the genes related to kidney functions showed region-related differences in their expression and some of them were consistent with previous reports. There are also many genes with unique region-related differences in the table, which have not been described in the literature and it would be worthwhile to start new investigations based on these data. In the present study, analysis of gene expression was exclusively done in non-treated animals. It is of course important to investigate the regional difference in the responsiveness to drugs, and it should be the highest priority of future study. In conclusion, comprehensive comparison data of gene expression in the renal anatomical areas would greatly enhance studies of physiological function and mechanism of toxicity in kidney.

## ACKNOWLEDGMENT

This study was supported in part by a grant from the Ministry of Health, Labor and Welfare (H14-Toxico-001).

## REFERENCES

- Echevarria, M., Windhager, E.E., Tate, S.S. and Frindt, G. (1994): Cloning and expression of AQP3, a water channel from the medullary collecting duct of rat kidney. *Proc. Natl. Acad. Sci. USA*, **91**, 10997-11001.
- Gu, S., Villegas, C.J. and Jiang, J.X. (2005): Differential Regulation of Amino Acid Transporter SNAT3 by Insulin in Hepatocytes. *J. Biol. Chem.*, **280**, 26055-26062.
- Harris, R.C., McKanna, J.A., Akai, Y., Jacobson, H.R., Dubois, R.N. and Breyer, M.D. (1994): Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. *J. Clin. Invest.*, **94**, 2504-2510.
- Ibarra, F., Crambert, S., Eklof, A.C., Lundquist, A., Hansell, P. and Holtback, U. (2005): Prolactin, a natriuretic hormone, interacting with the renal dopamine system. *Kidney Int.*, **68**, 1700-1707.
- Jo, I., Nielsen, S. and Harris, H.W. (1997): The 17 kDa band identified by multiple anti-aquaporin 2 antisera in rat kidney medulla is a histone. *Biochim. Biophys. Acta.*, **1324**, 91-101.
- Kanno, J., Aisaki, K., Igarashi, K., Nakatsu, N., Ono, A., Kodama, Y. and Nagao, T. (2006): "Per cell" normalization method for mRNA measurement by quantitative PCR and microarrays. *BMC Genomics*, **7**, 64.
- Karakashian, A., Timmer, R.T., Klein, J.D., Gunn, R.B., Sands, J.M. and Bagnasco, S.M. (1999): Cloning and characterization of two new isoforms of the rat kidney urea transporter: UT-A3 and UT-A4. *J. Am. Soc. Nephrol.*, **10**, 230-237.
- Nejsum, L.N., Elkjaer, M., Hager, H., Frokiaer, J., Kwon, T.H. and Nielsen, S. (2000): Localization of aquaporin-7 in rat and mouse kidney using RT-PCR, immunoblotting, and immunocytochemistry. *Biochem. Biophys. Res. Commun.*, **277**, 164-170.
- Schnellmann, R.G. (2001): Toxic responses of the kidney. In Casarett & Doull's Toxicology, 6th ed. (Klaassen, C.D., ed.), pp.491-514. McGraw-Hill.
- Snedecor, G.W. and Cochran, W.G. (1989): Statistical Methods, 8th ed., Iowa State University Press.
- Thukral, S.K., Nordone, P.J., Hu, R., Sullivan, L., Galambos, E., Fitzpatrick, V.D., Healy, L., Bass, M.B., Cosenza, M.E. and Afshari, C.A. (2005): Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. *Toxicol. Pathol.*, **33**, 343-355.
- Urushidani, T. and Nagao, T. (2005): Toxicogenomics: The Japanese initiative. In Handbook of Toxicogenomics - Strategies and Applications (Borlak, J., ed.), pp. 623-631. Wiley - VCH.
- van de Water, B., de Graauw, M., Le Devedec, S. and Alderliesten, M. (2006): Cellular stress responses and molecular mechanisms of nephrotoxicity. *Toxicol. Lett.*, **162**, 83-93.
- Xiong, W., Chao, L. and Chao, J. (1989): Renal kalikrein mRNA localization by in situ hybridization. *Kidney Int.*, **35**, 1324-1329.

## GENE EXPRESSION PROFILE IN LIVER OF DIFFERING AGES OF RATS AFTER SINGLE ORAL ADMINISTRATION OF ACETAMINOPHEN

Katsumi MORISHITA<sup>1</sup>, Yumiko MIZUKAWA<sup>2</sup>, Toshihiko KASAHARA<sup>1</sup>, Manabu OKUYAMA<sup>1</sup>,  
Kayoko TAKASHIMA<sup>1</sup>, Naoki TORITSUKA<sup>1</sup>, Toshikazu MIYAGISHIMA<sup>1</sup>,  
Taku NAGAO<sup>3</sup> and Tetsuro URUSHIDANI<sup>1,2</sup>

<sup>1</sup>Toxicogenomics Project, National Institute of Biomedical Innovation,  
7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan

<sup>2</sup>Department of Pathophysiology, Faculty of Pharmaceutical Sciences,  
Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto 610-0395, Japan

<sup>3</sup>National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

(Received August 18, 2006; Accepted September 11, 2006)

**ABSTRACT** — In order to verify the influence of the rat age on hepatotoxicity, male Sprague-Dawley rats of 6 (young) and 12 (adult) weeks of age were orally administered acetaminophen (APAP), isoniazid (INH), or carbon tetrachloride (CCl<sub>4</sub>). Liver samples were obtained in a time-course manner, and changes in gene expression examined by an Affymetrix GeneChip. APAP caused more prominent hepatic injury with respect to pathology and blood biochemistry in adults than in young rats, whereas no obvious age-related differences were observed in INH- or CCl<sub>4</sub>-treated rats. Comparing gene expression in control rats, CYP3A13 was higher and GSTY2c was lower in adults, suggesting that production of the active metabolite of APAP is higher and its detoxification is lower in adults. The total amount of glutathione and total SH in rat liver was found to be higher in adult rats whereas the extent of its reduction by APAP was larger in adults. A detailed analysis of genes showing age-related differences revealed that some of them were different not in their extent but in their time course, i.e., the stress responses occurred earlier in the young than in the adult, resulting in a difference at 24 hr after dosing. These results suggest that the age-related difference in toxicity would be attributed to a higher expression of CYP3A13, producing the active metabolite of APAP as well as the lower expression of the detoxification enzyme, GSTY2c, in adult rats. Furthermore, these differences affect the time course of APAP toxicity. The present study clearly depicts the advantage of the multi-time, multi-dose protocol employed in our project for analyzing the mechanism of toxicity by gene expression profiling.

**KEY WORDS:** Toxicogenomics, Acetaminophen, Hepatotoxicity, Age-related difference, Rat

### INTRODUCTION

The Toxicogenomics Project is a 5-year collaborative project by the National Institute of Health Sciences (NIHS) and 17 pharmaceutical companies in Japan which started in 2002 (Urushidani and Nagao, 2005). Its aim is to construct a large-scale toxicology database of transcriptome for the prediction of toxicity of new chemical entities in the early stage of drug development. About 150 chemicals, mainly medical compounds, have been selected, using both *in vitro*

studies with primary hepatocyte of rat and human, and *in vivo* studies in rat. Of these, the standard protocol of *in vivo* study in TGP consists of a single administration test and a repeated administration test with multi-time and multi-dose. The gene expression of the liver is comprehensively analyzed by using Affymetrix GeneChip® with the traditional toxicity parameters. Although the ages of the rats were varied in a time-course sacrifice between 6 to 10-weeks old, we did not previously know the age-difference effect in the susceptibility of hepatotoxicity. In starting of TGP, we

Correspondence: Tetsuro URUSHIDANI (E-mail: turushid@dwc.doshisha.ac.jp)

conducted an exploratory study to clarify whether the age-related difference was present in hepatotoxicity by using the first 3 chemicals in the TGP database, i.e., APAP, isoniazid (INH), and carbon tetrachloride (CCl<sub>4</sub>). Of these 3 chemicals, APAP alone showed a significant age-related difference in hepatotoxicity. In this report, we focus on the age-difference in susceptibility of APAP hepatotoxicity and elucidate the cause of the difference.

## MATERIALS AND METHODS

### Chemicals

APAP, INH, and CCl<sub>4</sub> were purchased from Sigma Co. Ltd., (St. Louis, MO). All other chemicals and reagents used in the present study were of HPLC or analytical grade and are commercially available.

### Animal treatment

Male Sprague-Dawley rats were purchased from Charles River Japan Inc., (Kanagawa, Japan) at 5-weeks or 11-weeks of age. After a 7-day quarantine and acclimatization period, the animals were divided into groups of 5 using a computerized stratified random grouping method based on body weights for each age. On the administration day, the animals were 6 and 12 weeks-old, respectively. The animals were individually housed in stainless-steel cages in a room that was lighted for 12 hr (7:00-19:00) daily, ventilated with an air-exchange rate of 15 times per hour, and maintained at 21 to 25°C with a relative humidity of 40 to 70%. Each animal was allowed free access to water and pellet food (CRF-1, sterilized by radiation, Oriental Yeast Co., Japan).

Five rats in each group were orally administered APAP or INH by suspending in 0.5% methylcellulose solution, and with CCl<sub>4</sub> by dissolving in corn oil. The highest dose level for each administration was determined by a 1 week dose-finding study (data not shown) and subsequently the middle and low doses were determined, i.e., 50, 300, 1000 mg/kg for APAP, 10, 50, 200 mg/kg for INH, and 30, 100, 300 mg/kg for CCl<sub>4</sub>. Blood samples were obtained at 3, 6, 9, and 24 hr post-dose with a needle and a heparinized syringe from the abdominal artery under ether anesthesia. Plasma was obtained after centrifugation and stored below -20°C until use. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) were determined by COBAS MIRA plus autoanalyzer (Roche Diagnostics, Basel, SZ). After blood collection, the animals were euthanized by

exsanguination from the abdominal veins and arteries under ether anesthesia. The liver samples were collected in 10% neutral buffered formalin at necropsy and embedded in paraffin, and then sectioned and stained with hematoxylin-eosin. Histopathological evaluation of the liver specimens was conducted by using light microscopy and graded as - (no change), + (minimal), + (slight), ++ (moderate), and +++ (severe).

### Measurement of hepatic glutathione and SH contents

The pre-weighed (ca. 0.1 g each) liver samples were homogenized with 5% 5-sulfosalicylic acid (Sigma-Aldrich), and centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was used for measurement of total glutathione (GSH) content in liver using the Total Glutathione Quantification Kit (Dojindo Laboratories) according to the manufacturer's instructions. In this kit, GSH oxidized by DTNB is reduced by glutathione reductase; namely, an enzyme recycling method is employed. We modified this method in order to measure the total free SH contents in the sample. In brief, the manufacturer's instructions were followed except that the glutathione reductase solution was replaced with a buffer solution and the dilution factor for the sample and GSH standard solutions was reduced ca. 1/5 - 1/10 fold. The reaction time was 10 min at room temperature and the measurement was done by a pseudo-end point method. The results were expressed as SH equivalent to the standard GSH per wet weight (g) in both measurements.

### Microarray experiment

An aliquot of the sample (about 30 mg) was obtained from the left lateral lobe of the liver of each animal immediately after sacrifice, and put into RNA later<sup>®</sup> (Ambion, Austin, TX, USA) overnight for 4°C and then frozen. Homogenization was conducted by Mill Mixer (Qiagen) and zirconium beads. The purity of the RNA was checked by gel electrophoresis, and the 260/280 nm ratio was between 2.0-2.2. Total RNA was isolated using RNeasy kit by Bio Robot 3000 (Qiagen, Valencia, CA, USA).

Microarray analysis was conducted on 3 out of 5 samples for each group by using GeneChip<sup>®</sup> RAE230A probe arrays (Affymetrix, Santa Clara, CA, USA) containing 15923 probe sets. The procedure was conducted basically according to the manufacturer's instructions. Briefly, 5 µg of total RNA was used for the synthesis of cDNA with the Superscript Choice

## Acetaminophen on gene expression profile in rat liver.

System (Invitrogen, Carlsbad, CA, USA) and T7-(dT)<sub>24</sub>-oligonucleotide primer (Affymetrix). After the cDNA was purified by cDNA Cleanup Module (Affymetrix), biotin-labeled cRNA was synthesized by using the BioArray High yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). The cRNA was purified by an IVT cRNA Cleanup Spin Column (Affymetrix), and then fragmented. Twenty µg of the fragmented cRNA was hybridized to a RAE230A probe array for 18 hr at 45°C at 60 rpm. After hybridization, the array was washed and stained by streptavidin-phycoerythrin using the Fluidics Station 400 (Affymetrix). Finally, the array was scanned by Gene Array Scanner (Affymetrix). The digital image files were processed by Affymetrix Microarray Suite version 5.0.

#### Statistical analysis

The data from biochemistry was expressed as the mean value of the 5 animals in each group. In the present experiments, the data of blood biochemistry showed large variations and we thus employed Mann-Whitney's U-test (Snedecor and Cochran, 1989) for analyzing the drug effects.

Gene expression data were analyzed by using GeneSpring<sup>®</sup> version 6.1 (Silicon Genetics, Santa Clara, CA, USA). Expression data was normalized by the mean value (global normalization; adjusted to an arbitrary value of 500). After filtering the genes by flags (present or marginal call at least 12 of the 24 samples in each experiment), the fold change determination to the concurrent control samples was performed in order to extract drug-related changes. In some cases, Student's *t*-test (Snedecor and Cochran, 1989) with Benjamin's adjustment ( $p < 0.05$ ) was also used for the age-difference comparison using the control samples.

## RESULTS

#### Phenotype change by APAP, INH and CCl<sub>4</sub>

Time-course changes in plasma AST, ALT and LDH after administrations of APAP, INH, and CCl<sub>4</sub> are shown in Table 1. In APAP-treated rats, significant increases of ALT and AST were noted in adult rats at 24 hr after treatment of 1000 mg/kg. Young rats treated with the same dosage showed a tendency of increment of these enzyme activities, but it was not statistically significant. In the cases of INH and CCl<sub>4</sub>, no obvious increase of these enzymes was detected. Although a significant statistical difference in young rats was detected 9 hr after INH-treatment, it was a decrease in

the measure and thus considered not to be toxic.

Histopathological findings of the liver are shown in Table 2. At 24 hr post-dose of APAP, necrosis, increased eosinophilia and vacuolation of hepatocyte were observed with inflammatory cells infiltration at 1000 mg/kg in both ages. Of these, hepatocyte necrosis in adult rats was more evident than that in young rats. In the young rats, minimal necrosis (grade +/-) was only noted in 2 out of 5 animals (Photo 1A), whereas all of the adult rats had necrosis: 2 of them were grade + (Photo 1B) and the remaining 3 were grade +/-.

No obvious changes were found in the liver with this dose range of INH. Although CCl<sub>4</sub> caused some pathological changes in the liver, no obvious age-related differences were noted. Both biochemistry and histopathology indicated that hepatotoxicity of APAP was evident, i.e., increases in the leak of the enzymes and centrilobular necrosis of hepatocytes, and adult rats appeared to be more susceptible to hepatotoxicity than the young ones.

#### Age-dependent gene expression

Based on the biochemical and histopathological data, the age-related difference appeared to be specific for APAP among the three chemicals. This suggested that there should be some difference in the factors specifically involved in APAP-induced hepatotoxicity. In order to elucidate the cause of the difference, we tried to extract genes with different expression by age from control animals.

Nine control animals in each time point were employed for both young and adult rats from the TGP database, and the genes that changed more than 2-fold between the ages with statistical significance ( $p < 0.05$ ) in all time points (3, 6, 9, and 24 hr) were extracted (Table 3). Of the total 11 genes extracted, 7 genes were lower and 4 genes were higher in adult rats than in young ones. They contained "hemoglobin beta chain complex" and "aminolevulinic acid synthase 2" (the rate-limiting enzyme in hepatic porphyrin-heme biosynthesis), both of which appeared to reflect the biosynthesis of red blood cells in the liver, and this appears to be reasonable, because extramedullary hematopoiesis decreases with age. As for changes related to APAP toxicity, it was noteworthy that the lower value of glutathione *S*-transferase Yc2 (GSTYc2) and the higher value of Cyp3A13 in adult rats were clearly indicated. Fig. 1 shows the time- and dose-dependent effects of APAP on the expression of these two genes. GSTYc2 (Fig. 1A) was found to be always higher in young than in adult rats. Nine hr after

**Table 1.** Changes in Blood biochemistry after treatment with 1000 mg/kg of Acetaminophen (APAP), 200 mg/kg of Isoniazid (INH) and 300 mg/kg carbon tetrachloride (CCl<sub>4</sub>).

Compound	Age (week)	Dose (mg/kg)	Time (hr)	Number of Animals	AST (IU/L)	ALT (IU/L)	LDH (IU/L)	
APAP	6	0	3	5	66.2 ± 9.6	35.0 ± 8.7	111.2 ± 47.3	
			6	5	63.4 ± 7.8	32.2 ± 4.1	105.2 ± 32.0	
			9	5	53.4 ± 4.2	28.6 ± 3.4	81.6 ± 24.0	
			24	5	59.0 ± 6.3	37.0 ± 3.1	105.2 ± 33.8	
		1000	3	5	66.2 ± 7.3	36.8 ± 5.2	88.2 ± 14.2	
			6	5	61.8 ± 4.2	31.2 ± 1.8	119.2 ± 21.4	
			9	5	60.2 ± 4.1	30.8 ± 5.9	107.2 ± 30.1	
			24	5	76.4 ± 14.1	51.0 ± 17.2	134.4 ± 31.9	
		12	0	3	5	68.4 ± 17.1	29.2 ± 5.4	115.6 ± 29.8
				6	5	56.6 ± 7.3	25.0 ± 2.5	122.6 ± 44.9
				9	5	52.6 ± 2.2	25.2 ± 2.2	100.8 ± 54.6
				24	5	65.6 ± 12.5	29.8 ± 5.3	122.8 ± 62.1
	1000		3	5	63.4 ± 11.1	30.8 ± 7.7	109.2 ± 24.7	
			6	5	58.6 ± 3.0	26.6 ± 3.8	93.0 ± 15.0	
			9	5	52.0 ± 3.7	26.4 ± 4.7	121.8 ± 62.2	
			24	5	287.8 ± 221.0 *	78.4 ± 62.3 *	315.4 ± 208.1	
	6		0	3	5	59.8 ± 7.2	34.0 ± 4.5	92.0 ± 19.8
				6	5	55.2 ± 7.2	26.8 ± 4.9	114.2 ± 36.1
				9	5	55.4 ± 5.0 *	27.4 ± 2.3	82.6 ± 29.5
				24	5	59.6 ± 8.2	33.2 ± 4.7	109.4 ± 46.5
		200	3	5	58.2 ± 5.8	31.4 ± 3.6	86.6 ± 22.9	
			6	5	50.0 ± 2.2	24.0 ± 2.0	92.0 ± 16.2	
			9	5	39.2 ± 6.7	24.6 ± 1.3	94.6 ± 26.1	
			24	5	47.6 ± 6.7	21.2 ± 6.6	96.0 ± 25.6	
INH		0	3	5	54.8 ± 10.5	25.0 ± 7.6	93.4 ± 44.9	
				6	5	49.8 ± 11.7	24.2 ± 3.6	87.0 ± 38.6
				9	5	46.0 ± 16.2	22.6 ± 4.4	112.0 ± 85.9
			12	3	5	50.8 ± 9.1	26.6 ± 9.7	99.0 ± 30.6
	6			5	51.2 ± 10.8	27.2 ± 4.0	85.2 ± 34.6	
	9			5	42.4 ± 3.6	22.4 ± 3.9	77.0 ± 29.2	
	200	9	5	29.0 ± 7.1	19.2 ± 4.9	83.0 ± 30.4		
			6	5	41.4 ± 11.0	14.2 ± 4.1	89.8 ± 41.2	
			24	5	66.6 ± 2.7	37.2 ± 7.2	209.0 ± 109.8	
		6	6	5	62.8 ± 5.1	31.4 ± 2.1	189.2 ± 78.5	
			9	5	62.6 ± 9.9	30.0 ± 4.2	163.0 ± 55.4	
			24	5	66.6 ± 4.0	37.2 ± 2.7	186.2 ± 67.2	
CCl <sub>4</sub>	300	3	5	67.8 ± 4.3	39.4 ± 4.5	201.4 ± 74.9		
			6	5	65.2 ± 5.7	29.8 ± 4.6	205.8 ± 48.3	
			9	5	63.2 ± 5.8	28.4 ± 1.5	200.2 ± 59.1	
		12	6	5	75.0 ± 13.3	42.2 ± 4.6	192.6 ± 38.2	
			9	5	73.0 ± 18.8	37.8 ± 7.6	156.6 ± 30.4	
			24	5	90.6 ± 38.4	47.6 ± 25.2	181.2 ± 32.5	
	0	9	5	131.8 ± 162.9	123.2 ± 206.7	239.6 ± 100.7		
			6	5	63.4 ± 10.6	34.6 ± 4.0	171.6 ± 51.0	
			24	5	65.6 ± 9.9	35.6 ± 5.7	213.2 ± 58.6	
		300	6	5	75.4 ± 21.1	37.0 ± 16.5	179.2 ± 71.4	
			9	5	72.6 ± 17.8	31.4 ± 10.7	235.8 ± 110.0	
			24	5	68.8 ± 1.5	36.6 ± 4.1	201.8 ± 60.6	

Data are expressed as mean ± SD of 5 measurements. \* p<0.05; significantly different from control by Mann-Whitney's U-test.



## Acetaminophen on gene expression profile in rat liver.

dosing, APAP clearly up-regulated the expression of the enzyme and the values after the induction were still higher in young than adult rats. In the case of CYP3A13, its expression was always lower in young

than in adult rats and was not affected by APAP at all (Fig. 1B).

In order not to miss other molecular species, the expressions of CYP and GST were checked. There are

**Table 2.** Histopathological changes of liver by 1000 mg/kg of acetaminophen (APAP), 200 mg/kg of isoniazid (INH) and 300 mg/kg of carbon tetrachloride (CCl<sub>4</sub>).

Compound	Age (Week)	Time (hr)	Findings	Number of animals									
				Grade	Control				High dose				
					-	±	+	++	-	±	+	++	
APAP	6	3	No abnormal findings										
		6	No abnormal findings										
		9	Increased eosinophilia of hepatocyte	5					2	3			
		24	Necrosis of hepatocyte	5					3	2			
			Increased eosinophilia of hepatocyte	5					1	2	2		
			Vacuolar change of hepatocyte	5						1			
		Inflammatory infiltration	5					4		1			
	12	3	No abnormal findings										
		6	No abnormal findings										
		9	No abnormal findings										
		24	Necrosis of hepatocyte	5						3	2		
			Increased eosinophilia of hepatocyte	5							2	3	
Vacuolar change of hepatocyte			5					4	1				
	Inflammatory infiltration	5						2	3				
INH	6	3	No abnormal findings										
		6	No abnormal findings										
		9	No abnormal findings										
		24	No abnormal findings										
	12	3	No abnormal findings										
		6	No abnormal findings										
		9	No abnormal findings										
		24	No abnormal findings										
		6	3	Degeneration, hydropic	5					2	2	1	
			6	Degeneration, hydropic	5					1	2	2	
CCl <sub>4</sub>	6	9	Cellular infiltration	5				4	1				
		6	Degeneration, hydropic	5				1	4				
	9	3	Degeneration, hydropic	5				4	1				
		6	Cellular infiltration	5				1	4				
		9	Degeneration, hydropic	5				1	4				
		24	Cellular infiltration	5				2	3				
	12	3	Degeneration, fatty	5					1	4			
		6	Degeneration, hydropic	5				2	2	1			
		9	Degeneration, hydropic	5				2	3				
		24	Cellular infiltration	5				1	4				
9		3	Degeneration, hydropic	5				3	2				
		6	Cellular infiltration	5					5				
		9	Degeneration, hydropic	5					2	3			
		24	Cellular infiltration	5					5				
	Degeneration, fatty	5					2	3					

Grade indication: no change (-), minimal (±), slight (+), moderate (++)

Table 3. Differentially expressed genes in control animals between 6 and 12 week-old rats.

Probe Set ID	Gene ID	Gene Symbol	Fold change vs. 6W									Gene Title	
			3H	6H	9H	24H	3H	6H	9H	24H	P-value		
1387123_at	NM_012753	Cyp17a1	0.23	0.34	0.26	0.24	3.9E-04	4.1E-02	1.6E-03	1.9E-03	1.9E-03	1.9E-03	cytochrome P450, family 17, subfamily a, polypeptide 1
1371089_at	AA945082	Yc2	0.21	0.28	0.15	0.30	2.4E-04	7.0E-03	3.5E-03	8.6E-03	8.6E-03	8.6E-03	glutathione S-transferase Yc2 subunit
1368160_at	NM_013144	Igfbp1	0.23	0.14	0.23	0.33	1.4E-03	2.0E-03	4.7E-02	2.8E-02	2.8E-02	2.8E-02	insulin-like growth factor binding protein 1
1371102_x_at	X05080	Hbb	0.42	0.43	0.27	0.35	9.4E-03	2.0E-03	7.9E-05	3.1E-03	3.1E-03	3.1E-03	hemoglobin beta chain complex
1371245_a_at	B1287300	---	0.45	0.39	0.24	0.38	1.4E-02	9.4E-04	3.4E-05	2.5E-03	2.5E-03	---	---
1367985_at	NM_013197	Alas2	0.42	0.41	0.32	0.42	7.0E-04	4.6E-03	2.5E-05	1.4E-03	1.4E-03	1.4E-03	aminolevulinic acid synthase 2
1387022_at	NM_022407	Aldh1a1	0.42	0.41	0.35	0.44	3.5E-03	1.2E-02	3.5E-03	1.1E-02	1.1E-02	1.1E-02	aldehyde dehydrogenase family 1, member A1
1369465_at	NM_012584	Hsd3b	2.6	2.4	2.7	2.0	1.9E-03	2.9E-02	1.7E-03	3.1E-02	3.1E-02	3.1E-02	steroid delta-isomerase, 3 beta
1390146_at	BF414998	RGD1306105_predicted	2.5	3.4	3.1	2.9	2.0E-03	1.6E-03	1.7E-03	1.1E-03	1.1E-03	1.1E-03	similar to RIKEN cDNA 2610318G18 (predicted)
1370387_at	U46118	Cyp3a13	6.4	5.1	4.7	3.4	1.4E-03	1.3E-02	3.0E-04	1.4E-03	1.4E-03	1.4E-03	cytochrome P450, family 3, subfamily a, polypeptide 13
1368171_at	NM_017061	Lox	2.7	5.6	7.4	3.6	1.9E-02	2.5E-02	7.9E-05	2.7E-02	2.7E-02	2.7E-02	lysyl oxidase

Nine control animals for each time point were employed for both young and adult rats from the TCP database, and the genes that changed more than 2-fold between the ages with statistical significance ( $p < 0.05$ , Student's *t*-test with Benjamin's adjustment) in all time points (3, 6, 9, and 24 hr) were extracted. Fold changes of 12-week vs. 6-week and their *p* values at each time point are also shown.

## Acetaminophen on gene expression profile in rat liver.

19 probe sets annotated with GST, while GSTYc2 was the only one with a difference between young and adult. A comparison between young and adult rats was made at 24 hr after the treatment with 1000 mg/kg of APAP and significant differences were detected in three GSTs, i.e., GST mu 2, microsomal GST 3 (predicted), and GST omega, all of which showed lower values in adult than in young rats (data not shown). There are 63 probe sets annotated with CYP, and only CYP17A1 and CYP2C40 (in addition to CYP3A13) were found to be differentially expressed between young and adult rats, and the former two had much lower values in adult than in young rats. No probe sets with different sensitivity to APAP treatment between ages were detected in CYPs. As CYP17A1 and CYP2C40 are involved in steroid biosynthesis and arachidonic acid metabolism, respectively, CYP3A13 was found to be the only candidate for CYP with age-related difference that produces active metabolites of APAP.

The above results could explain the observation that adult rats showed high sensitivity to APAP. In order to explain the specificity of the chemicals, we checked the expressions of CYP2E1 and *N*-acetyltransferase, which are considered to be involved in production of active metabolites of INH and/or CCl<sub>4</sub>. As described above, CYP2E1 had no age-related difference, and this was the same for the INH- or CCl<sub>4</sub>-


treated group. There are 6 probe sets annotated with *N*-acetyltransferase, and none of them showed significant age-related differences regardless of treatment with INH (data not shown).

**Measurement of GSH and SH**

It is a consensus that APAP is converted into an active metabolite that is detoxified by GSH conjugation and hepatotoxicity emerges when intracellular GSH is depleted. From the present results, it was suggested that adult rats had a high ability to produce the active metabolite but low capacity of detoxification and that subsequently this caused GSH-depletion more easily as compared with young rats. This was confirmed by direct measurements of hepatic GSH and SH contents by the DTNB method. The results are shown in Fig. 2. Both GSH and free SH contents per wet weight of liver in adult rats showed a value twice as high as that in young rats. Twenty-four hr after treatment with 1000 mg/kg of APAP, these measures did not change in young rats, whereas they showed a remarkable decrease in adults with a statistical significance in free SH contents. This supported our assumption that the high sensitivity to APAP in adult rats is attributed to the high degree of GSH-depletion.

**Gene expression changes by APAP**

Numbers of altered genes with 2-fold or more of




**Photo 1.** H&E-stained sections of rat liver 24 hr after oral administration of 1000 mg/kg APAP. A: 6-week-old rat; centrilobular necrosis +/-, eosinophilia ++, inflammatory infiltration +. B: 12-week-old rat; centrilobular necrosis +, eosinophilia ++, inflammatory infiltration +.

the corresponding control in the highest doses of APAP, INH, and CCl<sub>4</sub> are shown in Table 4. In this analysis, we did not use statistical filtering because we considered that it was favorable to overview the drug-related changes in order to compare the age difference between young and adult rats. The numbers of genes affected by APAP were greater in adult rats than those in young rats for all time points. In contrast, INH and

CCl<sub>4</sub> did not show any clear tendency in terms of the age-related difference in the numbers of mobilized genes.

The altered genes with more than 3-fold change vs. control at 24 hr post-dose of APAP in adult rats are listed in Table 5 (up-regulated genes), and those with less than 1/3 vs. control at 24 hr in adult rats are listed in Table 6 (down-regulated genes). The fold change of



**Fig. 1.** Time- and dose-dependent effects of APAP on the expression of glutathione *S*-transferase Yc2 (1371089\_at) and Cyp3a13 (1370387\_at). Rats 6- or 12-week-old were treated with 50 (low), 300 (middle) and 1000 (high) mg/kg of APAP and sacrificed at 3, 6, 9, and 24 hr after treatment. Gene expression in liver was analyzed by using GeneChip® RAE230A probe arrays and the signals obtained by Affymetrix Microarray Suite version 5.0 were normalized by using the mean value of each chip adjusted to an arbitrary value of 500 and expressed as mean  $\pm$  SD (N=3).

## Acetaminophen on gene expression profile in rat liver.

each gene in young rats is also included in these tables. Response to oxidative stress (Hsp1a, Hsp1b, Hmx1, Txnrd1, Hspb8, Hspca, Hspb8), glutathione metabolism (Gss, Gstp, Gsr, Gclc), and response to DNA damage (Ddit4, Prp19, Apex1, Gadd45a) were up-regulated in adult rats. Cell proliferation (pcna, Nap111, Gnl3), part of glutathione metabolism (Gsr, Gclc), UDP-glucuronocyltransferase (RGD:708541, RGD:708417) were up-regulated in both young and adult rats. However, microsomal enzymes (Cyp7A1, Cyp3A11, Cyp17A1, Comt, Gulo, G6pc, Sec11, RGD:2467, G6pc, Fmo1, Gulo) and mitochondrial enzymes (Glul, Oat, Ehhadh, Abcc8, Otc, Abat, Ivd, Abcc9, Aadat, Ca5a, Acsl1) were dominantly down-regulated in adult rats. Of these, some mitochondrial enzymes (Oat, Ehhadh and Ivd) were also down-regulated in young rats. These results indicated that the gene expression changes in adult rats were also greater than those in young ones, reflecting the degree of liver damage.

Changes of some representative genes are depicted as Fig. 3 and Fig. 4, which show time- and dose-dependency. In genes such as Egr1, Dnajb1 (predicted), Ddit3, and Hspca (Fig. 3A-D), their expression was highly up-regulated 24 hr after treatment of the highest dose and the extent of induction was remark-

ably different between ages. On the other hand, in the genes such as Hsp a1a, Hmx-1, Gadd45, and Txnrd (Fig. 4A-D), their induction was larger in adult than young 24 hr after treatment, whereas induction in the young ones occurred at an earlier time point than the adults, i.e., the extent of induction of these genes were much higher in the young than in the adult at early time points. Namely, part of the protective response against APAP started earlier in young rats.

By analyzing the time- and dose-dependent manner, it was revealed that some of stress-related genes responded faster in young than adult rats by APAP. Since expression of these genes was not affected by INH or CCl<sub>4</sub>, it was not a feature of young rats but rather specific for APAP among these chemicals. Furthermore, reviewing the histopathology in Table 2, cell infiltration with minimal extent occurred at 9 hr only in the young rats, supporting the result of the above gene expression analysis.

## DISCUSSION

The mechanism of hepatotoxicity by APAP has been proposed in some papers (Cohen and Khairallah, 1997; Parkinson, 2001; Bessems and Vermeulen, 2001; Irwin *et al.*, 2004). The most widely accepted mecha-




Fig. 2. Effects of APAP on hepatic content of total glutathione and SH of 6- and 12-week-old rats.

Both 6- or 12-week-old rats received 1000 mg/kg APAP orally and liver samples obtained 24 hr later. A: total glutathione contents expressed as  $\mu\text{mol}$  glutathione per g wet weight, B: total SH contents equivalent to  $\mu\text{mol}$  glutathione per g wet weight. Values are mean  $\pm$  SD (N=3). A statistically significant reduction of total SH was observed in 12-week rats ( $p < 0.05$ ).

nism is that APAP is biotransformed to a reactive intermediate (*N*-acetyl-*p*-benzoquinone imine) by cytochrome P450s (Cyp2E1 and Cyp3A) in liver. The main detoxification pathway is considered to be GSH-conjugation. Finally, overflow of intermediate and/or depletion of GSH cause protein arylation and/or oxidation, and subsequently leads to necrosis of the liver. Expression changes by APAP in the present study were generally in agreement with the above mechanism of action, i.e., response to oxidative stress, glutathione metabolism, response to DNA damage, cell proliferation, and

conjugation enzymes were up-regulated and several microsomal enzymes and mitochondrial enzymes were down-regulated. Of these, down-regulation of several microsomal enzymes and mitochondrial enzymes could be explained by the organelle function, because the microsome was the place where the reactive metabolite was produced and cell death was closely related to mitochondrial damage (Jaeschke and Bajt, 2006). These changes by APAP were also greater in adult rats than in young rats at 24 hr after dosing.

Although there have been several studies where hepatotoxicity of APAP in rodent was analyzed by gene expression (Reilly *et al.*, 2001; Ruepp *et al.*, 2002; Irwin *et al.*, 2004; Heinloth *et al.*, 2004), there is a limited number of papers regarding the age difference in the susceptibility of hepatotoxicity. A few papers described age-related differences such as weanling vs. mature (Allameh *et al.*, 1997), 11-day vs. 33-day-old (Green *et al.*, 1984), or 4-month vs. 25-month-old rats (Rikans and Moore, 1988), but the cause of the differences was not well clarified (Rikans, 1989; Tarloff *et al.*, 1996). There was no information about the difference in susceptibility concerning young to mature age, either. As 6 week-old rats are generally used for toxicological tests (and thus we employ this age for creating our toxicogenomics database), we are interested in the sensitivity of rats of this age against hepatotoxicants compared with matured rats, such as 12-week-olds.

In the present study, a single oral dose of APAP at 1000 mg/kg caused marginal hepatotoxicity in young rats, such as a tendency for an increase in plasma enzymes and minimal hepatocyte necrosis. Under the same condition, adult rats showed more prominent toxicity. This age-related difference should be based on APAP-specific mechanism(s), since no age-related differences were noted in INH or CCl<sub>4</sub>-induced hepatotoxicity. From the present results and literatures, the main mechanism was considered to be as follows: a) the expression of CYP3A13 that produces the active metabolite of APAP is higher in adult than in young rats, b) among the GST species that detoxify the active metabolite of APAP, the expression of GSTYc2 is lower in adult than in young, and c) the expression of GST, mu 2, microsomal GST 3 (predicted), GST omega 1 are inhibited by APAP.

The modification of APAP toxicity by modifying Cyp3A has been reported in rodents. Inhibition of Cyp3A prevented APAP hepatotoxicity (Kostrubsky *et al.*, 1997), whereas caffeine, dexamethazone, troglitazone or pregnenolone 16 alpha-carbonitrile, all of

**Table 4.** Number of genes whose expression was changed more than 2-fold by 1000 mg/kg of APAP, 200 mg/kg of INH or 300 mg/kg of CCl<sub>4</sub>.

Compound	Age (week)	Time (hr)	Number of Genes		
			Increased	Decreased	
APAP	6	3	27	67	
		6	14	32	
		9	19	39	
		24	137	149	
	12	3	32	88	
		6	33	198	
		9	34	67	
		24	220	193	
	INH	6	3	15	17
			6	6	13
			9	5	25
			24	3	34
12		3	4	15	
		6	1	20	
		9	18	19	
		24	6	62	
CCl <sub>4</sub>		6	3	15	25
			6	10	73
			9	5	31
			24	21	39
	12	3	34	24	
		6	4	24	
		9	14	12	
		24	9	64	

Expression data was normalized by mean value (global normalization; adjusted to an arbitrary value of 500) and filtering of the genes by flags (present or marginal call at least 12 of the 24 samples in each experiment) was performed. The fold change of each of the probe sets by the drug was calculated and the numbers of the genes showing more than 2-fold or less than half of control value were counted for each age.

Acetaminophen on gene expression profile in rat liver.

**Table 5.** List of genes that showed expression of more than 3-fold of control by APAP at 24 hr at 12-week-old rats.

Probe Set ID	Gene Symbol	Gene ID	Fold change		Gene Title
			6W	12W	
1368247_at	Hspa1a /// Hspa1b_mapped	NM_031971		37.3	heat shock 70kD protein 1A /// heat shock 70kD protein 1B (mapped)
1370912_at	Hspa1b_mapped	BI278231		30.0	heat shock 70kD protein 1B (mapped)
1368321_at	Egr1	NM_012551		17.3	early growth response 1
1372510_at	Srxn1	AI172302	2.7	17.0	Sulfiredoxin 1 homolog (S. cerevisiae)
1383302_at	Dnajb1_predicted	BM384926		12.4	DnaJ (Hsp40) homolog, subfamily B, member 1 (predicted)
1387060_at	Klf6	NM_031642		10.1	Kruppel-like factor 6
1370080_at	Hmox1	NM_012580		9.3	heme oxygenase (decycling) 1
1368160_at	Igfbp1	NM_013144	4.0	8.8	insulin-like growth factor binding protein 1
1370436_at	LOC246263	AF062389	3.1	8.4	kidney-specific protein (KS)
1386321_s_at	Trib3	H31287	3.9	7.9	tribbles homolog 3 (Drosophila)
1388986_at	---	AI598339		7.8	Transcribed locus
1367856_at	G6pdx	NM_017006	2.9	7.8	glucose-6-phosphate dehydrogenase X-linked
1389528_s_at	Jun	BI288619		7.7	Jun oncogene
1367795_at	Ifrd1	NM_019242		7.4	interferon-related developmental regulator 1
1388271_at	---	BM383531	4.4	7.3	---
1374404_at	Jun	BI288619		6.9	Jun oncogene
1388722_at	Dnajb1_predicted	AA945704		6.8	DnaJ (Hsp40) homolog, subfamily B, member 1 (predicted)
1368308_at	Myc	NM_012603		6.4	myelocytomatosis viral oncogene homolog (avian)
1368947_at	Gadd45a	NM_024127		6.4	growth arrest and DNA-damage-inducible 45 alpha
1386958_at	Txnrd1	U63923		6.4	thioredoxin reductase 1
1368121_at	Akr7a3	NM_013215	5.2	6.3	aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)
1368718_at	Aldh1a4	M23995		6.2	aldehyde dehydrogenase family 1, subfamily A4
1370688_at	Gclc	J05181	2.7	5.9	glutamate-cysteine ligase, catalytic subunit
1375852_at	Hmger	BM390399		5.9	3-hydroxy-3-methylglutaryl-Coenzyme A reductase
1371785_at	Tnfrsf12a	BI303379		5.3	tumor necrosis factor receptor superfamily, member 12a
1368124_at	Dusp5	NM_133578		5.3	dual specificity phosphatase 5
1398343_at	Dnaja4	AI104324		5.0	DnaJ (Hsp40) homolog, subfamily A, member 4
1374433_at	RGD1563902_predicted	BI301532		4.9	Similar to Ferritin light chain (Ferritin L subunit) (predicted)
1369590_a_at	Ddit3	NM_024134		4.7	DNA-damage inducible transcript 3
1398791_at	Txnrd1	NM_031614		4.6	thioredoxin reductase 1
1387282_at	Hspb8	NM_053612		4.5	heat shock 22kDa protein 8
1387599_a_at	Nqo1	J02679	4.2	4.5	NAD(P)H dehydrogenase, quinone 1
1387022_at	Aldh1a1	NM_022407	2.2	4.5	aldehyde dehydrogenase family 1, member A1
1390026_at	Bag3	AI231792		4.3	Bcl2-associated athanogene 3
1370030_at	Gclm	NM_017305	4.4	4.3	glutamate cysteine ligase, modifier subunit
1388850_at	Hspca	BG671521		4.3	heat shock protein 1, alpha
1388898_at	Hsph1	AI236601		4.2	heat shock 105kDa/110kDa protein 1
1384427_at	Mdm2_predicted	BI296301		4.2	transformed mouse 3T3 cell double minute 2 homolog (mouse) (predicted)

Table 5. Continued.

Probe Set ID	Gene Symbol	Gene ID	Fold change		Gene Title
			6W	12W	
1370583_s_at	Abcb1 /// Abcb1a	AY082609	3.6	4.1	ATP-binding cassette, sub-family B (MDR/TAP), member 1 /// ATP-binding cassette, sub-family B (MDR/TAP), member 1A
1368147_at	Dusp1	BE110108		4.1	dual specificity phosphatase 1
1388721_at	Hspb8	BG380282		4.1	heat shock 22kDa protein 8
1368213_at	Por	A1407454		4.1	P450 (cytochrome) oxidoreductase
1372523_at	Gclc	AA892770	2.2	4.0	glutamate-cysteine ligase, catalytic subunit
1386995_at	Btg2	BI288701		4.0	B-cell translocation gene 2, anti-proliferative
1386922_at	Ca2	A1408948	4.5	4.0	carbonic anhydrase 2
1387283_at	Mx2	NM_134350	2.0	3.9	myxovirus (influenza virus) resistance 2
1372389_at	Ier2	BF420059		3.6	immediate early response 2
1371237_a_at	Mt1a	AF411318	4.5	3.6	metallothionein 1a
1372261_at	---	A1409067	2.7	3.5	Transcribed locus
1373473_a_at	Nap111	BM386384	2.1	3.5	nucleosome assembly protein 1-like 1
1367733_at	Ca2	NM_019291	3.2	3.5	carbonic anhydrase 2
1373810_at	Pla2g12a_predicted	BF284175	3.6	3.5	phospholipase A2, group X1IA (predicted)
1377092_at	---	BF389682		3.4	Transcribed locus
1388622_at	Nol5a	AW535890		3.4	nucleolar protein 5A
1389573_at	Chac1_predicted	A1170665		3.4	ChaC, cation transport regulator-like 1 (E. coli) (predicted)
1375895_at	---	BI275908		3.3	CDNA clone IMAGE:7302535, with apparent retained intron
1368332_at	Gbp2	NM_133624		3.3	guanylate nucleotide binding protein 2
1369061_at	Gsr	NM_053906	2.2	3.3	glutathione reductase

Fold changes in 6-week-old rats are also shown for values higher than 2.

which are Cyp3A inducers, increased APAP hepatotoxicity (Jaw and Jeffery, 1993; Madhu *et al.*, 1993; Jue *et al.*, 2002; Guo *et al.*, 2004). Therefore, it would be reasonable to assume that the difference in basal expression levels of Cyp3A13 between young and adult rats accounts for the difference in susceptibility to APAP toxicity. Cyp2E1 is another enzyme responsible for biotransformation, i.e., inhibition of Cyp2E1 decreased the production of a reactive metabolite in the liver microsome from humans (Hazai *et al.*, 2002), although this enzyme did not show an age-difference. Based on the present results, participation of CYP3A is considered to be larger than that of CYP2E in the rat.

GSTYc2 was one isoform of glutathione S-transferase, and was known to play an important role in aflatoxin detoxification (Buetler and Eaton, 1992; Hayes *et al.*, 1992 and 1994). Although the role of GSTYc2 in APAP detoxification has not been investigated, it could have some role as GST conjugation, a key detoxification pathway of the reactive intermediate

of APAP.

When the total of the GST and SH-contents in the liver were measured, they were found to be higher in adult than in young under the control condition, while their reduction by APAP-treatment was larger in adult than in young. This could be explained by our assumption from gene expression analysis that the production of active metabolite is higher and the rate of the supply of the detoxification enzyme is lower in adult rats.

The age-related difference in the number of mobilized genes at 24 hr after APAP-treatment was considered to be correlated with the phenotype. Namely, most of these changes in the expression reflected the results of pathological changes. When the precise analysis of the genes showing age-related difference was made in terms of time- and dose-related responses, another view emerged. Among the genes with age-related difference at 24 hr after APAP-treatment, there were not only genes with differing levels of expression but also differences in the response time.



## Acetaminophen on gene expression profile in rat liver.

**Table 6.** List of genes that showed expression of less than 0.3-fold of control by APAP at 24 hr in 12-week-old rats.


Probe Set ID	Gene Symbol	Gene ID	Fold change		Gene Title
			6W	12W	
1371412_a_at	Nrep	BE107450	0.25	0.06	Neuronal regeneration related protein
1386977_at	Ca3	NM_019292	0.20	0.08	carbonic anhydrase 3
1374251_at	---	AA893192		0.11	Transcribed locus
1367896_at	Ca3	AB030829		0.13	carbonic anhydrase 3
1369864_a_at	Sds	NM_053962	0.47	0.17	serine dehydratase
1387665_at	Bhmt	U96133	0.40	0.18	betaine-homocysteine methyltransferase
1374244_at	LOC501038	AI411141	0.35	0.18	Ab2-060
1376976_at	Sectm1	AI009823		0.18	secreted and transmembrane 1
1373686_at	Serpina6_mapped	AA893495	0.42	0.19	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 (mapped)
1389681_at	Pvrl2	BI296388	0.24	0.21	Poliovirus receptor-related 2 (herpesvirus entry mediator B)
1368171_at	Lox	NM_017061	0.33	0.21	lysyl oxidase
1374531_at	---	AA926305		0.22	Transcribed locus
1368826_at	Comt	NM_012531		0.22	catechol-O-methyltransferase
1393221_at	RGD1564865_predicted	AA866264		0.23	similar to 20-alpha-hydroxysteroid dehydrogenase (predicted)
1368458_at	Cyp7a1	NM_012942	0.45	0.23	cytochrome P450, family 7, subfamily a, polypeptide 1
1368172_a_at	Lox	BI304009		0.25	lysyl oxidase
1373778_at	---	BE349670	0.32	0.26	Transcribed locus
1368270_at	Apobec1	NM_012907		0.26	apolipoprotein B editing complex 1
1373814_at	RGD1310066	BI291270		0.26	similar to mKIAA1002 protein
1398759_at	Tgfb1i4	NM_013043	0.34	0.27	transforming growth factor beta 1 induced transcript 4
1388583_at	Cxcl12	BF283398	0.42	0.27	chemokine (C-X-C motif) ligand 12
1368778_at	Slc6a6	NM_017206	0.34	0.27	solute carrier family 6 (neurotransmitter transporter, taurine), member 6
1368543_at	Nox4	NM_053524		0.27	NADPH oxidase 4
1375560_at	RGD1310475_predicted	AA945579		0.28	similar to RIKEN cDNA 0610010D20 (predicted)
1388426_at	Srebfl	BF398848	0.50	0.28	sterol regulatory element binding factor 1
1387053_at	Fmo1	NM_012792		0.28	flavin containing monooxygenase 1
1375216_at	Pvrl2	AA850909	0.31	0.28	poliovirus receptor-related 2 (herpesvirus entry mediator B)
1387263_at	Pklr	NM_012624		0.28	pyruvate kinase, liver and red blood cell
1374493_at	---	H35017		0.29	Transcribed locus
1369664_at	Avpr1a	NM_053019	0.36	0.30	arginine vasopressin receptor 1A
1377015_at	Me3_predicted	BF395080	0.43	0.30	Malic enzyme 3, NADP(+)-dependent, mitochondrial (predicted)
1371137_at	Acox2	X95189		0.30	acyl-Coenzyme A oxidase 2, branched chain
1372684_at	Smtn	AW435036		0.30	smoothelin
1387123_at	Cyp17a1	NM_012753	0.30	0.30	cytochrome P450, family 17, subfamily a, polypeptide 1
1367729_at	Oat	NM_022521	0.30	0.30	ornithine aminotransferase
1374625_at	Hes6	AI176616	0.47	0.30	hairy and enhancer of split 6 (Drosophila)
1373975_at	LOC368066	AI232716		0.30	similar to thioether S-methyltransferase

Fold changes in 6-week-old rats are also shown for values lower than 0.5.

Especially, genes related to defensive responses to stress, e.g., heat shock protein, Hmx-1, Gadd45, and thioredoxin reductase were markedly induced by APAP in young rats at 6 or 9 hr after treatment, whereas adult rats did not respond as yet. This is considered to be due to the age-related difference in the toxicokinetics, i.e., young rats responded to APAP in the early stage of exposure because of the low SH level but recovered at 24 hr because of the high detoxification capacity.

In the case of CCl<sub>4</sub>, its active metabolite is reported to be produced by CYP2E1 (Parkinson, 2001) and this fits the present observation that neither the

expression of CYP2E1 nor hepatotoxicity of CCl<sub>4</sub> showed a difference between the ages. Although GSH conjugation should play an important role in their detoxification, the participation of GSTYc2 is considered to be less important for CCl<sub>4</sub> in rats. It has been reported that both *N*-acetylation and CYP2E1 are involved in hepatotoxicity of INH (Parkinson, 2001). In the present study, no age-related difference was found in the expression of *N*-acetylating enzymes and CYP2E1, in accordance with the same extent of hepatotoxicity of INH for both ages. However, one should be careful in these conclusions, since phenotypical changes by INH and CCl<sub>4</sub> were minimal in the present



**Fig. 3.** Time- and dose-dependent effects of APAP on expression of *Egr1* (A), *Dnajb1* (predicted) (B), *Ddit3* (C), and *Hspca* (D). Rats 6- or 12-week-old were treated with 50 (low), 300 (middle) and 1000 (high) mg/kg of APAP and sacrificed at 3, 6, 9, and 24 hr after treatment. Gene expression in liver was analyzed by using GeneChip® RAE230A probe arrays and the signals obtained by Affymetrix Microarray Suite version 5.0 were normalized by using the mean value of each chip adjusted to an arbitrary value of 500 and then expressed as mean  $\pm$  SD (N=3). Note that the expression of these genes was markedly increased by APAP-treatment at 24 hr in adult (12-week-old) rats.

## Acetaminophen on gene expression profile in rat liver.

condition, which was optimized for their repeated administration for up to 28 days in our standard protocol.

The TGP database has huge gene expression data as well as the traditional toxicity study parameters, currently for over 100 chemicals. Although the main purpose of the project is to predict toxicity in the early stage of drug development, it is also useful for drawing some mechanistic insight in observed toxicity. In the present study, it would have been impossible to pick up such genes responding in a different time course with age, unless a multi-time, multi-dose protocol was employed. In general, dose or time points tend to be limited in the collection of toxicological data by


microarray due to the cost. The present study has clearly showed the advantage of our protocol with enough numbers of data points. This promises a good use for our database now being created in the project.

## ACKNOWLEDGMENT

This work was supported in part by a grant from the Ministry of Health, Labour and Welfare, H14-tox-ico-001.

## REFERENCES

Allameh, A., Vansoun, E.Y. and Zarghi, A. (1997):



**Fig. 4.** Time- and dose-dependent effects of APAP on expression of Hsp a1a/a1b (A), Hmx-1 (B), Gadd45 (C), and Txnrd (D). Rats 6- or 12-week-old were treated with 50 (low), 300 (middle) and 1000 (high) mg/kg of APAP and sacrificed at 3, 6, 9, and 24 hr after treatment. Gene expression in liver was analyzed by using GeneChip® RAE230A probe arrays and the signals obtained by Affymetrix Microarray Suite version 5.0 were normalized by using the mean value of each chip adjusted to an arbitrary value of 500 and then expressed as mean  $\pm$  SD (N=3). Note that the induction of these genes by APAP at 24 hr was larger in adult (12-week-old) than young (6-week-old) rats, whereas the young rat responded to APAP earlier.

- Role of glutathione conjugation in protection of weanling rat liver acetaminophen-induced hepatotoxicity. *Mech. Ageing Dev.*, **95**, 71-79.
- Bessemers, J.G.M. and Vermeulen, N.P.E. (2001): Paracetamol (acetaminophen)-induced toxicity: Molecular and biochemical mechanisms, analogues and protective approaches. *Crit. Rev. Toxicol.*, **31**, 55-138.
- Buetler, T.M. and Eaton, D.L. (1992): Complementary DNA cloning, messenger RNA expression, and induction of alpha-class glutathione S-transferases in mouse tissues. *Cancer Res.*, **52**, 314-318.
- Cohen, S.D. and Khairallah, E.A. (1997): Acetaminophen. In (Sipes, I.G., McQueen, C.A. and Gandolfi, A.J., eds.), *Comprehensive Toxicology*, **9**, Pergamon, Elsevier Science Inc. pp.329-343.
- Green, M.D., Shires, T.K. and Fischer, L.J. (1984): Hepatotoxicity of acetaminophen in neonatal and young rats. I. Age-related changes in susceptibility. *Toxicol. Appl. Pharmacol.*, **74**, 116-124.
- Guo, G.L., Moffit, J.S., Nicol, C.J., Ward, J.M., Aleksunes, L.A., Sliitt, A.L., Kliewer, S.A., Manautou, J.E. and Gonzalez, F.J. (2004): Enhanced acetaminophen toxicity by activation of the pregnane X receptor. *Toxicol. Sci.*, **82**, 374-380.
- Hayes, J.D., Judah, D.J., Neal, G.E. and Nguyen, T. (1992): Molecular cloning and heterologous expression of a cDNA encoding a mouse glutathione S-transferase Yc subunit possessing high catalytic activity for aflatoxin B1-8,9-epoxide. *Biochem. J.*, **285**, 173-180.
- Hayes, J.D., Nguyen, T., Judah, D.J., Petersson, D.G. and Neal, G.E. (1994): Cloning of cDNAs from fetal rat liver encoding glutathione S-transferase Yc polypeptides. The Yc2 subunit is expressed in adult rat liver resistant to the hepatocarcinogen aflatoxin B1. *J. Biol. Chem.*, **269**, 20707-20717.
- Hazai, E., Vereczkey, L. and Monostory, K. (2002): Reduction of toxic formation of acetaminophen. *Biochem. Biophys. Res. Commun.*, **291**, 1089-1094.
- Heinloth, A.N., Irwin, R.D., Boorman, G.A., Fannin, R.D., Sieber, S.O., Snell, M.L., Tucker, C.J., Li, L., Travlos, G.S., Vansant, G., Blackshear, P.E., Tennant, R.W., Cunningham, M.L. and Paules, R.S. (2004): Gene expression profiling of rat livers reveals indication of potential adverse effects. *Toxicol. Sci.*, **80**, 193-202.
- Irwin, R.D., Boorman, G.A., Cunningham, M.L., Heinloth, A.N., Malarkey, D.E. and Paules, R.S. (2004): Application of toxicogenomics to toxicology: Basic concepts in the analysis of microarray data. *Toxicol. Pathol.*, **32** (suppl. 1), 72-83.
- Jaeschke, H. and Bajt, M.L. (2006): Intracellular signaling mechanisms of acetaminophen-induced liver cell death. *Toxicol. Sci.*, **89**, 31-41.
- Jaw, S. and Jeffery, E. (1993): Interaction of caffeine with acetaminophen. *Biochem. Pharmacol.*, **46**, 493-501.
- Jenner, P.J. and Ellard, G.A. (1989): Isoniazid-related hepatotoxicity: A study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man. *Tubercle*, **70**, 93-101.
- Jue, L., Kaneko, T., Wang, Y., Qin, L-Q., Wang, P-Y. and Sato, A. (2002): Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. *Toxicology*, **176**, 91-100.
- Kostrubsky, V.E., Szakacs, J.G., Jeffery, E.H., Woods, S.G., Bement, W.J., Wrighton, S.A. and Sinclair, J.F. (1997): Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. *Tox. Appl. Pharmacol.*, **143**, 315-323.
- Madhu, C., Maziasz, T. and Klassen, C. (1993): Effect of pregnenolone-16 alpha-carbonitrile and dexamethasone on acetaminophen-induced hepatotoxicity in mice. *Tox. Appl. Pharmacol.*, **115**, 191-198.
- Parkinson, A. (2001): Biotransformation of xenobiotics. In (Klaassen, C.D., ed.), *Casarett and Doull's Toxicology Chapter 6*, 6<sup>th</sup> edition pp.133-224, McGraw-Hill.
- Reilly, T.P., Bourdi, M., Brady, J.N., Pise-Masison, C.A., Radonovich, M.F., George, J.W. and Pohl, L.R. (2001): Expression profiling of acetaminophen liver toxicity in mice using microarray technology. *Biochem. Biophys. Res. Commun.*, **282**, 321-328.
- Rikans, L.E. and Moore, D.R. (1988): Acetaminophen hepatotoxicity in aging rats. *Drug. Chem. Toxicol.*, **11**, 237-247.
- Rikans, L.E. (1989): Influence of aging on chemically induced hepatotoxicity: Role of age-related changes in metabolism. *Drug Metabolism Reviews*, **20**, 87-110.
- Ruepp, S.U., Tonge, R.P., Shaw, J., Wallis, N. and Pognan, F. (2002): Genomics and proteomics